Corteva, Inc. · NYSE:CTVA
Corteva — Investor Day (September 2026)
76 slides from Corteva's investor day presentation, Sep 15, 2026
Slide 1: Investor Day 2026
Investor Day 2026 September 15 | New York City
Slide 2: Welcome and Opening Remarks
OPTION 3 2 Welcome and Opening Remarks Headshot Rafa Soares Head of Investor Relations and FP&A 2026 INVESTOR DAY 2
Slide 3: Safe Harbor Regarding Forward-Looking Statements
Safe Harbor Regarding Forward-Looking Statements Forward-Looking Statements This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, whi
Slide 4: Reminder About Non-GAAP Statements
Reminder About Non-GAAP Statements Regulation G (Non-GAAP Financial Measures) This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include operating EBITDA and operating EBITDA margin. Management uses these measures intern
Slide 5: Today's Agenda
Today’s Agenda 1:00 PM Welcome and Opening Remarks | Rafa Soares, Head of Investor Relations and FP&A 1:05 PM Corteva Strategy Review | Luke Kissam, Chief Executive Officer 1:25 PM Innovation Built to Outpace What's Next | Reza Rasoulpour, Chief Technology Officer 1:45 PM Commercial Excellence and C
Slide 6: Launching Corteva with momentum
Launching Corteva with momentum Luke Kissam Chief Executive Officer 2026 INVESTOR DAY 6
Slide 7: Launching Corteva with momentum
Launching Corteva with momentum 1 Focused, pure-play crop protection company with proven track record 2 Innovation pipeline positioned to drive sustainable and profitable growth Providing customer-focused solutions creates the opportunity for 3 enhanced value capture C 4 Unrelenting focus on enterpr
Slide 8: A focused, pure-play crop protection company
A focused, pure-play crop protection company ~9,000 REVEN UE Employees BY GEOGRAPH Y 1 BY PORT FOLI O T YPE 1 ~110 12% 36% 22% Insecticides Countries APAC North America >25 50% 15% 21% Herbicides Fungicides EMEA 31% 7% Biologicals R&D Sites Around the Globe Latin America 1% 5% Other Seed Applied Tec
Slide 9: Track record of execution through a challenging market environment
Track record of execution through a challenging market environment TRACKING 2024 INVESTOR DAY PROMISES REVENUE 1 ($B) ~3% CAGR OPERATING ~6% CAGR OPERAT IN G ~250 bps EBITDA 1, 2 ($B) EBIT DA MARGIN 1 , 2 ~$7.7 $550M New Products Growth $6.5 ~$1.4 ~18% by 2027 15.5% $1.0 $300M run-rate cost of goods
Slide 10: The answer is innovation
Farmers face increasing challenges every season. The answer is innovation. Market Outlook Collective 1%-3% growth to 2035, led by 6%-8% growth Crop Protection Demand Drivers in Biologicals and 3%-5% in Seed Applied Technology Global CP Market Size Global agricultural Weather and climate Resistance a
Slide 11: A history of translating innovation into value
A history of translating innovation into value Past Decade Next Decade 7 new actives vs ~5 peer avg 7 new active ingredients + 5 new Biologicals ArylexTM, ZorvecTM, RinskorTM, PyraxaltTM, HavizaTM, KinrayzaTM, VarpelgoTM, RimisoxafenTM+ 3 new InatreqTM, ReklemelTM and AdaveltTM conventional chemistr
Slide 12: Differentiated pipeline supports growth
Differentiated pipeline supports growth ~$11B CP Pipeline1 ~$8B CP WEED DISEASE INSECT SEED APPLIED Pipeline BIOLOGICALS CONTROL CONTROL CONTROL TECHNOLOGY Arylex® & Rinskor Inatreq & Zorvec Pyraxalt & Reklemel Utrisha®N LumiTreo , Lumiposa Commercialized/ Expanding global Advancing na
Slide 13: Differentiated solutions lead to growth and expanded margins
Differentiated solutions lead to growth and expanded margins Differentiation of portfolio drives value INDEXED OPERATING EBITDA MARGIN (2) DIFFERENTIATED 1 140 • New Products make up ~1/3rd of differentiated portfolio ~65% • Biologicals largely included, with above-average margins 120 of revenue • R
Slide 14: Disciplined capital allocation framework
Disciplined capital allocation framework Sustained Organic growth and Return cash to Focused M&A Capital innovation shareholders 2-3% of revenue for safety, Replenish R&D pipeline and Grow dividend over time Accretive investments in maintenance, growth and accelerate successful launches supplemented
Slide 15: Experienced management with strong industry experience
Experienced management with strong industry experience LEADERSHIP TEAM BOARD OF DIRECTORS Luke Jeff Brook Karen Greg Klaus David Janet Jean-Marc Kissam Rudolph Cunningham Narwold Page Engel Everitt Giesselman Gilson Chief Executive Chief Financial Chief Commercial Chief Legal & Public Retired Chairm
Slide 16: Focused Innovation and Value Capture
Focused Innovation and Value Capture Focused on solving grower’s toughest challenges Proven innovation engine with an $11 billion pipeline Focus on attractive market segments that reward differentiation Diverse and balanced portfolio THREE VALUE DRIVERS Capital Discipline Operational Excellence One
Slide 17: Corteva is ready to grow from a position of strength
Corteva is ready to grow from a position of strength A Business that Delivers – Global crop protection company with track record of 2029 FRAMEWORK 1 performance through the cycle ~6% Operating Robust $11B pipeline – Unique innovation capabilities that turn discovery into EBITDA1 CAGR 2 sustainable a
Slide 18: Innovation built to outpace what's next
Innovation built to outpace what’s next Dr. Reza Rasoulpour Chief Technology Officer 2026 INVESTOR DAY 18
Slide 19: The challenges of the future won't be solved with yesterday's solutions
The challenges of the future won’t be solved with yesterday’s solutions CASE STUDY FARMER BROWN PLANTHOPPER IMPACT IN RICE (APAC)1 CHALLENGES Pest pressure is evolving Resistance is accelerating Novel mode of action helps growers combat a growing resistance challenge Weather volatility is changing t
Slide 20: Innovation focused on advancing crop health across four high value areas
Corteva innovation focused on advancing crop health across four high value areas $26B market opportunity 1 $27B market opportunity 1 Our Focus Areas: Our Focus Areas: • Resistance management and emerging pest threats • Emerging disease pressure • Out licensing to adjacent markets such as animal • Yi
Slide 21: A differentiated R&D engine that consistently creates value
A differentiated R&D engine that consistently creates value Outline of today’s presentation Proven track record of driving growth through 1 innovation Differentiated technology platforms that fuel our 2 R&D engine Transforming innovation Case studies of how differentiated technology solves 3 into cu
Slide 22: A proven track record of driving growth through innovation
1 A proven track record of driving growth through innovation 7 FUTURE GROWTH New actives launched in past decade1 VALUE CREATED 2020 – 2026E 2026 AND BEYOND 7 6 6 6 CAPTURING VALUE NEW PRODUCTS ~$11B Pipeline value through 20406 3 1 $1.4B 1000+ ~$2B 2 2 2026E New product New products revenue2 launch
Slide 23: Three proprietary R&D platforms powering our competitive advantage
2 Three proprietary R&D platforms powering our competitive advantage Microbial Integrated Predictive Discovery Platform Development Platform Safety Platform6 AI-powered capabilities across process Integrated safety capabilities that embed WHAT Microbial library of ~700,0001 strains provides a unique
Slide 24: Disease Control: Haviza active sets a new standard for Asian Soybean Rust
3 Disease Control: Haviza active sets a new standard for Asian Soybean Rust (ASR) LAUNCHING ~2028 ASR PROTECTION AND OVER 2% YIELD INCREASE2 >$500M PEAK REVENUE3 Untreated soybeans Competitor standard Haviza active1 LAUNCHING SOON: A NEX T-GENERATION FUNGICIDE FOR SOYBEAN GROWERS 1 Haviza active has
Slide 25: Insect Control: Varpelgo active delivers a broad-spectrum insect solution
3 Insect Control: Varpelgo active delivers a broad-spectrum insect solution across multiple crops Tomatoes LAUNCHING EARLY 2030s Untreated Competitor standard Protected with Varpelgo active1 70+ CROPS3 Additional crops and application types for Varpelgo active 40+ COUNTRIES3 Cabbage in United States
Slide 26: Weed Control: Nature-inspired active with novel mode-of-action
3 Weed Control: Nature-inspired active with novel mode-of-action Discovery Pipeline Herbicide LAUNCHING MID 2030s >$1.7B TAM3 Uncontrolled Corteva's nature-inspired herbicide-resistant weeds Competitor standard1 herbicide2 LAUNCHING NEX T DECADE: NEW DISCOVERY HERBICIDE WILL COMBAT WEED RESISTANCE 1
Slide 27: Plant Performance: Utrisha N is driving nutrient use efficiency
3 Plant Performance: Utrisha®N is driving nutrient use efficiency Potatoes in Germany Typical fertilizer Typical fertilizer + Utrisha N1 LAUNCHED 25% Extra fertilizer ~3.0 t/ha yield increase1 & RAMPING Additional crop uses for Utrisha® N Onions in Germany Soybeans in Brazil Grapes in Italy Coffee i
Slide 28: Corteva's ~$11B pipeline provides multiple pathways to value creation
4 Corteva’s ~$11B1 pipeline provides multiple pathways to value creation EARLY DISCOVERY PHASE2 DISCOVERY PHASE DEVELOPMENT PHASE LAUNCH & RAMP UP LIFECYCLE MANAGEMENT3 VALUE Innovative formulations, product extensions, Disease Control and portfolio complement and refresh. ~$2.4B Onmira , Inatreq ,
Slide 29: External innovation expands the potential of our pipeline
4 External innovation expands the potential of our pipeline EARLY DISCOVERY DISCOVERY PHASE DEVELOPMENT PHASE LAUNCH & RAMP UP CORTEVA CATALYST 4 PHASE1 Selective investments in disruptive startups that Disease Control complement and expand our early discovery pipeline. AH Company Insect Control CP
Slide 30: Corteva generates superior pipeline value per R&D dollar
5 Corteva generates superior pipeline value per R&D dollar PIPELINE VALUE 1 R&D SPEND 1 R&D EFFICIENCY 1 Peak sales potential 34% 2025 R&D Spend 33% Pipeline Value ÷ R&D Spend >2X THAN AVERAGE THAN AVERAGE THAN AVERAGE $14B 22.6X $1018M $919M COMPETITOR AVG $11B $728M $10B COMPETITOR AVG $8.2B $705M
Slide 31: Corteva is positioned to lead the next generation of crop health innovation
Corteva is positioned to lead the next generation of crop health innovation Proven ability to translate innovation into growth 7 active ingredient launches in the last decade demonstrate ability to consistently convert innovation into value Differentiated R&D platforms that fuel competitive advantag
Slide 32: Translating innovation into customer value
Translating innovation into customer value Brook Cunningham Chief Commercial Officer 2026 INVESTOR DAY 32
Slide 33: We grow through cycles by building a commercial engine
We grow through cycles — Not by predicting them, but by building a commercial engine that performs in all of them We operate in a structurally growing market that rewards 1 differentiated technology that solves farmer challenges Our balanced, differentiated portfolio drives above-peer 2 growth with
Slide 34: Sustained demand for differentiated technology in a growing market
Sustained demand for differentiated technology in a growing market Structural Market Drivers Fueling Our Business Capturing Growth Across Multiple Value Pools GLOBAL CP MARKET SIZE $B USD Population Arable land isn’t growing, but the world is ALL S EGMEN T S Growth 1-3% 115 BIOLOGICALS 101 Rising Pe
Slide 35: We compete based on differentiated technology, portfolio balance and segmentation
OUR COMMERCIAL MODEL We compete based on differentiated technology, portfolio balance and intentional market and crop segmentation to drive above-peer average growth ~65% +144 First Mover Above Peer Average Differentiation1 mix 2025-’29E New CP Products in 2025 In low margin product exits Price & vo
Slide 36: We win by delivering integrated solutions through tailored routes-to-market
OUR COMMERCIAL MODEL We win by delivering integrated solutions through tailored routes-to-market by country, supported by data-driven decision-making OUR PEOPLE INTEGRATED SOLUTIONS Our structural • Best team in the industry • Conventional CP + SAT + biologicals advantage Better growth • Deep techni
Slide 37: Shifting resources toward on-farm demand generation activities
OUR COMMERCIAL MODEL Shifting resources toward on-farm demand generation activities; Combining sales and agronomy to maximize farmer ROI in targeted crops/geographies Our Demand Generation Engine Translating Next Generation Commercial Excellence into Tangible Results: Selected Pilots1 Trusted and un
Slide 38: Accelerating launch capabilities and advancing lifecycle management
OUR COMMERCIAL MODEL Accelerating launch capabilities and advancing lifecycle management will shorten time to peak revenue and maximize lifetime value of technology Focus Markets: On-Patent On-Patent (Extend) Mature Generic WHERE (Launch to Peak Revenue) Full value capture Bridge to next- Commoditiz
Slide 39: Continued innovation and new product launches compound over time
CORTEVA PIPELINE ILLUSTRATION Continued innovation and new product launches compound over time NEW PRODUCTS 1 Overlapping ramps …Value of new launches …Continuously Bringing New Mixtures and increases over time…. Formulations Post-IP Expiry Defends Lifetime Value… GROWTH HIGHLIGHTS build sales… Peak
Slide 40: Scale leadership and increased freedom to operate in the U.S.
U.S. Scale leadership and increased freedom to operate where technology adoption rewards our portfolio STRATEGIC CHOICES TO WIN TAM1 • Large, consolidated farms • Storable commodities (corn, ~$15B soybeans, and wheat) • Three-step channel Freedom • Deeper channel partner strategy to Operate • Reimag
Slide 41: Winning through tailored go-to-market partnerships in Brazil
BRAZIL Winning through tailored go-to-market partnerships and deep market segmentation North/Cerrado STRATEGIC CHOICES TO WIN TAM • Mega-scale farms ~$14B • Broad-acre crops (soybeans, corn, cotton) Driving • Mega Growers (Personali) • Direct sales model Direct Sales • Financing Tools (Barter Now ~3
Slide 42: Tailoring our playbook to win across diverse markets
REST OF WORLD Tailoring our playbook to win across diverse markets EMEA Profile: Opportunities Driven by External Forces APAC Profile: Full Maturity Spectrum in One Region TAM EU-27: Small, high-value family TAM China: Blend of smallholder and farms, regulation and larger modernizing farms ~$20B sus
Slide 43: Commercial flywheel: farmer insights in, technology out
COMMERCIAL FLYWHEEL COMMERCIAL TEAM Commercial WORKS WITH CHANNEL AND FARMERS insights into farmer needs informs key R&D investment FREE CASH FLOW FUNDS NEXT IDENTIFICATION OF FARMER decision-making R&D WAVE PAIN POINTS while sales fund the Farmer next wave of new technology COMMERCIAL INFORMS R&D M
Slide 44: Building on strong foundation of Operational Excellence
Building on strong foundation of Operational Excellence Ralph Ford Chief Integrated Operations Officer 2026 INVESTOR DAY 44
Slide 45: Operational excellence converts innovation into shareholder value
Operational excellence converts innovation into shareholder value Integrated Operations integrates all facets of operations into an agile 1 platform to maintain resilience Our platform has made extensive strides to transition 2 from heritage to world class systems and processes, enabling the enterpr
Slide 46: Journey from legacy functions to one integrated platform
Journey from a collection of legacy functions to one integrated platform KEY CHANGES OUR STARTING POINT WHERE WE ARE TODAY Suboptimized active ingredient and Exited high-cost facilities, and optimized Rationalizing Heritage Footprint formulation & packaging network with internal and external network
Slide 47: One platform, built on a strong foundation and proven operating model
One platform, built on a strong foundation and a proven operating model One Integrated Operations Platform STRUCTURAL FOUNDATION EXECUTION MODEL Network and Operational Excellence Optimized systems and processes NETWORK OPTIMIZATION OPERATIONS EXCELLENCE SUPPLY RESILIENCE PRODUCTIVITY ENGINE Utilize
Slide 48: Two networks, one platform
Two networks, one platform KEY THEMES Protect IP and cost competitiveness through ACTIVE INGREDIENT NETWORK FORMULATION & PACKAGING NETWORK strategic partnerships Optimized footprint to: Close to end markets and Build resilient supply chains customers to create: through diversified sourcing Safeguar
Slide 49: We committed to $300M in savings, and are on track to deliver more
We committed to $300M in savings, and we are on track to deliver more Results achieved through: COST ACTIONS - INCREMENTAL OPERATING EBITDA 1 IMPROVEMENT • Value Driven prioritization of cost and supply actions • Strategic Category Management Sourcing ~$500M • Rationalizing heritage footprint to ali
Slide 50: Managing every molecule to its highest value throughout its lifecycle
Managing every molecule to its highest value throughout its lifecycle WHERE WE DRIVE VALUE HOW WE DRIVE VALUE Technology Continuous cost improvement of molecule and Launch with a cost advantage Continuously improve over Increase yields; cut cycle formulation & packaging processes through full the li
Slide 51: Cost journey of a new molecule
Cost journey of a new molecule COST REDUCTION HIGHLIGHTS Per Unit Cost Index UNIT COST REDUCTION Primary Driver Technology and Operational >80% 100 700 Excellence 90 600 • Chemistry Route New 80 Advancements to protect IP Molecule 500 70 • Continuous improvement to drive yield up, cycle time down, 6
Slide 52: Cost journey of a post-patent molecule
Cost journey of a post-patent molecule COST REDUCTION HIGHLIGHTS Per Unit Cost Index UNIT COST REDUCTION Primary Driver Strategic Sourcing 100 >40% 600 • Increased multi-sourcing and 90 re-sourcing qualified suppliers Post-Patent 500 Molecule 80 • Drive cost savings to 70 Formulation Level, not just
Slide 53: Our Integrated Operations Platform creates a competitive advantage
Our Integrated Operations Platform creates a competitive advantage • Protects our innovation and IP after commercialization What it • Creates resiliency through footprint and strategic sourcing does • Drives cost down throughout all phases of product lifecycle Enabling • Our process is repeatable an
Slide 54: Financial framework
Financial framework Jeff Rudolph Chief Financial Officer 2026 INVESTOR DAY 54
Slide 55: Corteva is well-positioned for value creation
Corteva is well-positioned for value creation Strong track record demonstrated through innovation, 1 execution and financial performance 2 Differentiated portfolio and pipeline support profitable growth Operating discipline translates innovation into EBITDA margin 3 expansion and meaningful cash flo
Slide 56: What we have delivered since 2020
What we have delivered since 2020 REVENUE ($B) OPERATING EBITDA 2 ($B) OPERATING EBITDA MARGIN 2 ~$7.7 ~$7.8 ~$1.4 ~$1.3 $6.5 ~18% ~17% $1.0 15.5% ~3% ~6% CAGR CAGR ~250 bps 20201 2026E1 2026E3 20201 2026E1 2026E3 20201 2026E1 2026E3 Stand-alone Stand-alone Stand-alone INDUSTRY-LEADING PERFORMANCE D
Slide 57: Above peer average performance built on innovation-driven mix
Above peer average performance built on innovation- driven mix and operational excellence REVENUE 1 GROWTH INDEXED TO 2020 OPERATING EBITDA 1, 2 MARGIN INDEXED TO 2020 Captured revenue growth in-line with peer average 150 140 despite portfolio exits 140 130 130 120 120 110 110 100 Drove performance
Slide 58: Setting the stage: 2026E Revenue
Setting the stage: 2026E Revenue1 2026 REVENUE BY INDICATION ($B) 2026 REVENUE BY REGION ($B) 2026 REVENUE BY CROP ($B) Biologicals Seed Applied Technology APAC North America Other Fruits & Veg. Fungicides Other Rice ~$7.8 ~$7.8 Soybeans ~$7.8 EMEA Insecticides Herbicides Corn Latin America Non-Crop
Slide 59: Market assumptions 2027 – 2029
Market assumptions 2027 – 2029 Industry growth normalizes at LSD annually Biologicals (HSD) and seed applied technologies (MSD) outpace growth in conventional CP On-farm demand remains steady Operating EBITDA1 growth Price largely stabilizing over the planning period assumptions largely reflect cont
Slide 60: 2029 Financial framework
2029 Financial framework REVENUE ($B) ~3% OPERATING EBITDA 1 ($B) ~6% CAGR CAGR @ Mid-Point @ Mid-Point KEY ASSUMPTIONS New Products ~$8.4 - $8.7 Launch / expansion of new ~$1.45 - $1.65 technologies globally ~$7.8 Biologicals ~$1.3 18.2% Continued ramp, led by Brazil Operating EBITDA Margin1 @ Mid-
Slide 61: Revenue growth outlook
Revenue growth outlook REVENUE BRIDGE ($B) KEY ASSUMPTIONS ~$8.4 - 16% CAGR, ~$800M $8.7 in New Product2 sales growth Biologicals Base Currency Business1 Double-digit CAGR Biologicals volume growth in all ~$7.8 regions New Products Base Business Pressured by lost registrations / cannibalization and
Slide 62: Operating EBITDA growth outlook
Operating EBITDA1 growth outlook OPERATING EBITDA 1 BRIDGE KEY ASSUMPTIONS ($B) New Products & Biologicals ~$1.45 - Biologicals Net COGS / Base $1.65 incremental margin of ~$450M Productivity Business2 SARD / ~$1.3 New Currency / Other >$200M in COGS Products Improvements from productivity, net of i
Slide 63: Strategically deploying capital to accelerate value creation
Strategically deploying capital to accelerate value creation SOURCES AND USES OF CASH 2027 – 2029 BALANCE SHAREHOLDER RETURNS AND TARGETED M&A Dividend Buybacks M&A $2.2 – $2.6B Grow over time Return excess cash to Strategic Fit shareholders + clear returns ~55% M&A / Share repurchases UNDERPINNED B
Slide 64: Corteva is ready to grow from a position of strength
Corteva is ready to grow from a position of strength A Business that Delivers – Global crop protection company with track record of 2029 FRAMEWORK 1 performance through the cycle ~6% OPERATING Robust $11B pipeline – Unique innovation capabilities that turn discovery into EBITDA1 CAGR 2 sustainable a
Slide 65: Appendix
Appendix 2026 INVESTOR DAY 65
Slide 66: Luke Kissam
Luke is chief executive officer of Corteva, a global leader in crop protection, differentiated by its comprehensive portfolio of innovative and sustainable solutions. Headshot To this role, Luke brings extensive experience in specialty chemicals as well as agriculture. He previously served as chairm
Slide 67: Dr. Reza Rasoulpour
Reza is Corteva's chief technology officer, leading the company's global research & development organization and innovation strategy. He oversees Corteva's end-to-end innovation engine spanning discovery, development, and Headshot product safety and stewardship. He also champions Corteva Catalyst ,
Slide 68: Brook Cunningham
Brook is Corteva’s chief commercial officer, overseeing the company’s global sales and marketing, commercial excellence, crop protection and plant health segments, business development and customer engagement organizations to deliver value for farmers and channel partners and to drive growth and Hea
Slide 69: Ralph Ford
Ralph is Corteva’s chief integrated operations officer leading its global supply chain, manufacturing, procurement and integrated operational excellence Headshot organization. Within this group he also oversees the facilities, services and real estate, and environment, health, safety and security te
Slide 70: Jeff Rudolph
Jeff is chief financial officer for Corteva, coming into the role with more than 15 years of experience in finance at Corteva and its heritage companies. Most Headshot recently, he served as chief strategy officer, where he led enterprise strategy, mergers and acquisitions, economic and competitive
Slide 71: New product introductions position Corteva for growth
New product introductions position Corteva for growth FRUIT & REGION PEAK NTR 2 ($M) CORN SOYBEANS CEREALS VEGETABLES RICE OTHERS Arylex active NA, LA, EMEA, AP $$$ Weed Control Bexoveld active1 NA, LA, EMEA, AP $ Rinskor active NA, LA, EMEA, AP $$$ Adavelt active NA, LA, EME
Slide 72: Trademark notices
® Trademark of Corteva Agriscience and its affiliated companies. Always read and follow label directions. © 2026 Corteva. Bexfond® biological fungicide is not for sale or use in all states. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your
Slide 73: Reconciliation to Segment Operating EBITDA
Corteva, Inc. Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Segment Operating EBITDA Six Months Ended June 30, Twelve Months Ended December 31, 2026 2025 2025 2024 2023 2022 2021 2020 In millions ‘As Reported | As Reported | As Reported | As Reported | As Reported
Slide 74: Reconciliation to Segment Operating EBITDA: Significant items
Corteva, Inc. Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Segment Operating EBITDA Significant items ‘Six Months Ended June 30, “Twelve Months Ended December 34, In milions 2028 2025 2025 2024 2023 2022 2021 2020 Restructuring and asset related charges - net ' S$
Slide 75: Reconciliation to Segment Operating EBITDA: Significant items
Corteva, Inc. Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Segment Operating EBITDA Significant items ‘Six Months Ended June 30, ‘Twelve Months Ended December 31, In millions 2026 2025 2025 2024 2023 2022 2021 2020 Restructuring and asset related charges - net" s
Slide 76: Reconciliation of Segment Profitability
€ Corteva, Inc. Reconciliation of Segment Profitability ‘$ In millions Seed Crop Protection Total For the Six Months Ended June 30, 2026 ‘$In millions Seed Crop Protection Net sales s 7,555 |S 3,729 |$ 14,284 Cost of goods sold 2,893 2,162 5,055 Other expenses * 1,662 791 2,453 [Segment oper EBITDA